ArticleJournal of medical biochemistry2026
The influence of platelet-rich fibrin combined with hydroxychloroquine on the inflammatory response; bone metabolism; and cell differentiation ability in temporomandibular joint osteoarthritis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to explore the regulatory effects of platelet-rich fibrin (PRF) on serum inflammatory response, bone metabolic balance and cell differentiation ability in patients with temporomandibular joint osteoarthritis (TMJ-OA) at the molecular level. Methods: Sixty patients were randomly divided into Group A and Group B (30 cases in each group). Group A was treated with meloxicam dispersible combined with hydrox-ychloroquine sulfate (HCQ); Group B was supplemented with autologous PRF intra-articular injection on the basis of Group A. Fasting venous blood was collected before treat-ment and 3 months after treatment. Inflammatory and bone metabolism markers such as IL-ip, IL-6, TNF-a, OPG, OPN, ALP and Runx2 were detected by e L iSA, and coagulation indicators such as A PTT and PT were deter-mined by an automatic coagulation analyzer. Results: After treatment, the inflammatory factors (IL-ip, IL-6, TNF-a) in both groups decreased significantly, but the decrease in group B was more significant (P< 0.05). Bone metabolism indicators showed that the improvement in group B was significantly better than that in group A (P< 0.05). Among the cell differentiation-related factors, the expression levels of Runx2, TGF-pi and Sox9 in group B were significantly increased compared with those before treatment (P< 0.05), and were higher than those in group A (P< 0.05). Conclusions: The use of PRF can optimize the therapeutic effect of TMJ-OA, improve inflammatory responses, promote cell differentiation and improve coagulation function parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.